Unveiling piperazine-quinoline hybrids as potential multi-target directed anti-Alzheimer’s agents: design, synthesis and biological evaluation
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-10927-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Afzal Nagani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, India. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Alzheimer Disease, Drug Design, Quinolines. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Multi-target directed ligands (MTDLs) have recently been popularized due to their outstanding efficacy in combating the complicated features of Alzheimer's disease. This study details the synthesis of piperazine-quinoline-based MTDLs through a multicomponent Petasis reaction, targeting multiple factors such as AChE, BuChE, metal chelation to restore metal dyshomeostasis, and antioxidant activity. Some of the synthesized compounds exhibited notable inhibitory activity against AChE and BuChE enzymes at specific concentrations. Among the synthesized compounds compound (95) containing a 4-chloroaniline moiety and a 4-methoxybenzyl group displayed the most promising inhibitory activities against AChE (IC50 3.013 µM) and BuChE (IC50 = 3.144 µM). Compound (83) featuring 2-methoxyaniline and 4-fluorobenzyl substituents, exhibited the highest BuChE inhibition (IC50 1.888 µM). Notably, compound (79) demonstrated 93-times higher selectivity for BuChE over AChE. Molecular docking and molecular dynamics simulations were also performed to explore the binding modes and stability of these compounds with the AChE amd BuChE proteins. Further, kinetics study was performed against AChE for comounds (83 and 95) which indicated mixed inhibition of the enzyme by these compounds, Amongs the synthesized compounds, nine compounds were assessed for their antioxidant activity, displaying significant antioxidant properties with IC50 values ranging from 156 µM to 310 µM. Moreover, all the compounds demonstrated metal chelating tendency with Cu+2, Zn+2, Fe+2, Fe+3 and Al+3. This study provides insights into the design of novel MTDLs, highlighting compound (95) as a potential candidate for combating Alzheimer's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, India.
- Research and Development Cell, Parul University, Vadodara, Gujarat, India.
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus, Changa, Anand, Gujarat, India.
- Sunnybrook Research Institute, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON, Canada.
- Faculty of Pharmacy, The M.S University of Baroda, Vadodara, Gujarat, India.
- Piramal Pharma Solution, Ahmedabad, Gujarat, India.
Zitieren
APA
Nagani, A., Shah, M., Patel, S., Patel, H., Parikh, V., Patel, A., Patel, S., Patel, K., Parmar, H., Bhimani, B., & Yadav, M. R. (2025). Unveiling piperazine-quinoline hybrids as potential multi-target directed anti-Alzheimer’s agents: design, synthesis and biological evaluation. Molecular Diversity. https://doi.org/10.1007/s11030-024-10927-4
Vancouver
Nagani A, Shah M, Patel S, Patel H, Parikh V, Patel A, et al. Unveiling piperazine-quinoline hybrids as potential multi-target directed anti-Alzheimer’s agents: design, synthesis and biological evaluation. Molecular Diversity. 2025. doi:10.1007/s11030-024-10927-4
BibTeX
@article{Nagani2025,
author = {Nagani, Afzal and Shah, Moksh and Patel, Salman and Patel, Harnisha and Parikh, Vruti and Patel, Ashish and Patel, Sagar and Patel, Kirti and Parmar, Hardik and Bhimani, Bhargav and Yadav, Mange Ram},
title = {Unveiling piperazine-quinoline hybrids as potential multi-target directed anti-Alzheimer’s agents: design, synthesis and biological evaluation},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-10927-4}
}
EUVIMED